Ingersoll-rand (ireland) Stock Earnings Reports

Ingersoll Rand delivered a solid start to 2026: Q1 revenue grew 8% year-over-year, adjusted EBITDA was $469M (25.4% margin) and adjusted EPS was $0.77 (up 7% YoY). Orders rose 5% with a book-to-bill of 1.07x; management disclosed roughly $40M of order delays tied to a handful of long‑cycle Middle East projects (about one‑third of that was recovered in April) and expects the remainder to be recovered through 2026. PST outperformed (Q1 organic revenue +4%, Life Sciences orders up double digits; PST EBITDA +15% YoY and margin improvement of ~120 bps). ITS saw margin pressure driven by flow‑through on lower organic volumes, tariff impacts and continued commercial investments, but short‑cycle demand showed stabilization and improvement (especially in U.S. compressors, vacuum/blower categories and China).

The company reaffirmed full‑year 2026 guidance: total revenue growth 2.5%–4.5% (organic ~1% midpoint), total adjusted EBITDA $2.13–$2.19B, adjusted EPS $3.45–$3.57 (≈5% growth at midpoint), adjusted tax rate ~23%, net interest ~ $230M, share count ~394M, and FCF conversion to adjusted net income ~95%. Balance sheet and cash flow remain strong (~$4B liquidity; leverage well below 2x); capital allocation priority remains M&A (robust funnel: ~200 targets, 10 LOIs, >90% internally sourced; expect 400–500 bps inorganic revenue in 2026) while continuing dividends and share repurchases. Management expects tariff/inflation mitigation actions and pricing to net roughly neutral to full‑year guidance today, with margin improvement weighted to the back half of 2026 as pricing, productivity initiatives and recovered volumes flow through.